{
 "name": "仲恩生醫",
 "slug": "tw-7729",
 "aliases": [
  "仲恩生醫科技股份有限公司",
  "SBI",
  "7729"
 ],
 "ticker": "7729",
 "industry": "生技醫療業",
 "website": "http://www.steminent.com",
 "summary": "仲恩生醫（7729）是興櫃的生技醫療類股公司，2007 年成立，2024 年登錄興櫃。基本資料取自臺灣證券交易所／證券櫃檯買賣中心公開資料；重大訊息見 https://drugnews.com.tw/filings/ 。",
 "facts": [
  {
   "claim": "公司全名",
   "value": "仲恩生醫科技股份有限公司",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "英文簡稱",
   "value": "SBI",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "產業類別",
   "value": "生技醫療業",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "掛牌市場",
   "value": "證券櫃檯買賣中心興櫃",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "登錄興櫃日期",
   "value": "2024-03-11",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "成立日期",
   "value": "2007-12-18",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "董事長",
   "value": "王玲美",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "總經理",
   "value": "柯景懷",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "實收資本額",
   "value": 806822410,
   "unit": "新台幣元",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "簽證會計師事務所",
   "value": "安侯建業聯合會計師事務所",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "公司網址",
   "value": "http://www.steminent.com",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "管線：Stemchymal（思脈能；脊髓小腦萎縮症）",
   "value": "脊髓小腦萎縮症｜臨床二期已完成、暫時性上市許可申請準備｜台灣",
   "unit": "",
   "as_of": "2026-06-10",
   "source": "https://steminent.com/resources/uploads/股東會/仲恩生醫-114年度年報.pdf",
   "note": "114年度年報第90頁（PDF第94頁）；台灣試驗NCT02540655。上市許可申請準備不等於已核准。"
  },
  {
   "claim": "管線：Stemchymal（美國脊髓小腦萎縮症）",
   "value": "多麩醯胺酸脊髓小腦萎縮症｜臨床二期已獲FDA准予執行、準備啟動｜美國",
   "unit": "",
   "as_of": "2026-06-10",
   "source": "https://steminent.com/resources/uploads/股東會/仲恩生醫-114年度年報.pdf",
   "note": "NCT06397274；年報第90頁。ClinicalTrials.gov最後發布2024-05-02仍為NOT_YET_RECRUITING；未聲稱已收案。"
  },
  {
   "claim": "管線：Stemchymal（腦中風）",
   "value": "腦中風｜規劃向TFDA申請臨床一期｜台灣",
   "unit": "",
   "as_of": "2026-06-10",
   "source": "https://steminent.com/resources/uploads/股東會/仲恩生醫-114年度年報.pdf",
   "note": "年報第90頁；雖表格開發進度欄列臨床I期，本fact以研發成果欄較明確的申請規劃中為準，不寫已啟動。"
  },
  {
   "claim": "管線：Stemchymal（亨丁頓舞蹈症）",
   "value": "亨丁頓舞蹈症｜臨床前開發｜地區未揭露",
   "unit": "",
   "as_of": "2026-06-10",
   "source": "https://steminent.com/resources/uploads/股東會/仲恩生醫-114年度年報.pdf",
   "note": "年報第90頁；地區未揭露。"
  },
  {
   "claim": "管線：Stemchymal（急性肺損傷）",
   "value": "急性肺損傷｜臨床前開發｜地區未揭露",
   "unit": "",
   "as_of": "2026-06-10",
   "source": "https://steminent.com/resources/uploads/股東會/仲恩生醫-114年度年報.pdf",
   "note": "年報第90頁；地區未揭露。"
  },
  {
   "claim": "管線：Enhanced Stemchymal",
   "value": "多麩醯胺酸相關疾病｜臨床前開發｜地區未揭露",
   "unit": "",
   "as_of": "2026-06-10",
   "source": "https://steminent.com/resources/uploads/股東會/仲恩生醫-114年度年報.pdf",
   "note": "年報第90頁；Enhanced Stemchymal列為臨床前開發，未有上市許可。"
  },
  {
   "claim": "管線：Stemchymal（急性肝衰竭）",
   "value": "急性肝衰竭｜一期試驗登錄已撤回｜台灣",
   "unit": "",
   "as_of": "2022-10-28",
   "source": "https://clinicaltrials.gov/api/v2/studies/NCT03629015",
   "note": "NCT03629015；登錄因公司策略考量撤回，並非已完成試驗。2026年報仍列TFDA核准、尋求合作，未有本次查得之重新啟動登錄證據。"
  },
  {
   "claim": "催化劑：Stemchymal（台日藥證）",
   "value": "台灣再生製劑附款許可及日本暫時性藥證取得目標｜2027（公司預估，最快）｜已公告",
   "unit": "",
   "as_of": "2026-06-10",
   "source": "https://steminent.com/resources/uploads/股東會/仲恩生醫-114年度年報.pdf",
   "note": "年報第93頁（PDF第97頁）；公司預估，非主管機關審查期限。"
  },
  {
   "claim": "催化劑：Stemchymal（製程擴充）",
   "value": "擴增新產線並導入優化2D生產流程｜2027（公司預估）｜已公告",
   "unit": "",
   "as_of": "2026-06-10",
   "source": "https://steminent.com/resources/uploads/股東會/仲恩生醫-114年度年報.pdf",
   "note": "年報第89頁（PDF第93頁）；製程擴產規劃。"
  },
  {
   "claim": "管線：Stemchymal（日本小腦萎縮症）",
   "value": "脊髓小腦性共濟失調症｜PMDA生產及銷售許可申請已送件｜日本",
   "unit": "",
   "as_of": "2026-06-24",
   "source": "https://mops.twse.com.tw/mops/#/web/t05st01",
   "note": "發言日期：2026-06-24 16:11:57；主旨：公告本公司獲代理商通知 -本公司新藥產品Stemchymal已向日本主管機關提出「生產及銷售許可申請」審查申請；公司代號7729；民國115年全年度；序號1。2026-09-26所公告MAH為授權夥伴的製造販賣業者資格，不是Stemchymal產品上市藥證。未自行從9個月流程推算核准日。"
  }
 ],
 "responses": [],
 "provided_by": "public_sources",
 "verified_by": "Drugnews｜藥時事",
 "verified_at": "2026-10-22",
 "disclosure": "Drugnews 依公開來源（公司公告、公開資訊觀測站、試驗登錄、主管機關文件）整理，於 verified_at 逐條核對來源；未經公司審閱。",
 "url": "https://drugnews.com.tw/companies/tw-7729.json",
 "generated_at": "2026-10-23T11:48:56.615Z"
}